Nasdaq vktx.

Dec 1, 2023 · In the previous quarter, Viking Therapeutics (NASDAQ:VKTX) missed the analysts' consensus estimate of ($0.22) by $0.01 with a reported earnings per share (EPS) of ($0.23). Learn more on analysts' earnings estimate vs. VKTX's actual earnings. Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock. SAN DIEGO , March 29, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic a... 8 months ago - PRNewsWire.Dec 1, 2023 · According to the issued ratings of 9 analysts in the last year, the consensus rating for Viking Therapeutics stock is Buy based on the current 9 buy ratings for VKTX. The average twelve-month price prediction for Viking Therapeutics is $30.25 with a high price target of $37.00 and a low price target of $19.00. Viking Therapeutics Inc (NASDAQ:VKTX) shares are trading higher Tuesday after the company reported results from its Phase 1 trial of VK2735 for the potential treatment of various metabolic disorders.Find the latest Insider Activity data for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.

Viking Therapeutics, Inc. Common Stock (VKTX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...

Find the latest Earnings Report Date for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.

Discover historical prices for VKTX stock on Yahoo Finance. View daily, weekly or monthly format back to when Viking Therapeutics, Inc. stock was issued. (NASDAQ: VKTX) Viking Therapeutics's 52-week high was $25.72, and its 52-week low was $3.54. It is currently -49.42% from its 52-week high and 267.51% from its ...Indeed, Viking Therapeutics (NASDAQ:VKTX) stock is up 246% in the last year, providing strong gains for shareholders. Nonetheless, only a fool would ignore the risk that a loss making company ...Jul 29, 2023 · Viking Therapeutics, Inc. (NASDAQ:VKTX), based in San Diego, California, is a clinical-stage company focused on the development of first-in-class or best-in-class therapies for metabolic and ... Jan 24, 2022 · What happenedInvestors didn't exactly launch a raid on Viking Therapeutics (NASDAQ: VKTX) stock during Monday's trading session. The shares tumbled by nearly 7% on the back of discouraging news ...

SAN DIEGO, Aug. 28, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of new results from the company's 12-week Phase 2 study of VK2809 in patients with non …

Viking Therapeutics (NASDAQ:VKTX) - Although it is a small-cap biotech firm Viking Therapeutics is a company that is involved in an interesting niche. It is involved in treating endocrine and metabolic disorders. At this point in time, ...

VKTX VKTX AFTER HOURS QUOTE VKTX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...Since the year began, shares of Viking Therapeutics (NASDAQ:VKTX) exploded from about $8 to about $25 a share.All thanks to its potential treatment for obesity, VK2735. So far, we know it works ...Strong Quarter-End Cash Position of $393M. SAN DIEGO, July 26, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the ...Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP agonist compound VK2735 for the ...

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb …Find the latest Viking Therapeutics, Inc. (VKTX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.About Institutional Holdings. Nasdaq provides the ownership stake information in a company, including the number of shares held by those institutions in a firm, along with recent purchases and ... Viking Therapeutics, Inc. (NASDAQ:NASDAQ:VKTX) Q4 2022 Results Conference Call February 8, 2023 4:30 AM ETCompany ParticipantsStephanie Diaz - Investor...The public float for VKTX is 89.39M and currently, short sellers hold a 18.98% ratio of that float. The average trading volume of VKTX on December 04, 2023 was 2.05M shares. VKTX) stock’s latest price update. Viking Therapeutics Inc (NASDAQ: VKTX)’s stock price has plunge by 9.99relation to previous closing price of 13.01.Viking Therapeutics, Inc. (NASDAQ: VKTX) is an American biotechnology company that is focused on the development of novel and orally available therapies for the treatment of metabolic and ...Clinical-stage biotech Viking Therapeutics (NASDAQ:VKTX) added 15% on Monday after Roche (OTCQX:RHHBY) agreed to acquire a peer obesity drugmaker Carmot Therapeutics (CRMO) in a up to $3.1B deal ...

VKTX U.S.: Nasdaq Viking Therapeutics Inc. Watch NEW Set a price target alert After Hours Last Updated: Dec 1, 2023 7:47 p.m. EST Delayed quote $ 13.10 0.09 0.69% After …

Viking Therapeutics, Inc. (NASDAQ:VKTX) shares were also up, gaining 42% to $12.92 after the company reported results from its Phase 1 trial of VK2735 for the potential treatment of various ...In the news. Yahoo Finance. 3 days ago. Viking Therapeutics, Inc. (NASDAQ:VKTX) is favoured by institutional owners who hold 74% of the company.Viking Therapeutics Inc stock price live 13.010, this page displays NASDAQ VKTX stock exchange data. View the VKTX premarket stock price ahead of the market session or assess the after hours quote.hace 2 días ... VKTXMercado de Valores Nasdaq • Precio de NLS en tiempo real • DIVISA EN USD • Biotechnology & Medical Research. Viking Therapeutics Inc (VKTX).Nov 21, 2023 · VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 55% based on the firm’s underlying fundamentals and the stock ... Viking Therapeutics Inc (NASDAQ: VKTX) (after the close) Thursday . Evelo Biosciences Inc (NASDAQ: EVLO) (before the market open) Baxter International Inc (NYSE: BAX) (before the market open)VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 72% based on the firm’s underlying fundamentals and the stock ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of new results from the ongoing Phase 2b clinical trial of VK2809, the company's novel liver-selective thyroid hormone receptor …

According to NASDAQ, as of May 2014, the highest NASDAQ closing ever was achieved on March 9, 2000, when the market closed at a record 5046.86. USA Today reports that the highest closing achieved by NASDAQ since was a 4007.09 closing on Nov...

Dec 1, 2023 · In the previous quarter, Viking Therapeutics (NASDAQ:VKTX) missed the analysts' consensus estimate of ($0.22) by $0.01 with a reported earnings per share (EPS) of ($0.23). Learn more on analysts' earnings estimate vs. VKTX's actual earnings. Strong Quarter-End Cash Position of $393M. SAN DIEGO, July 26, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the ...VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 55% based on the firm’s underlying fundamentals and the stock ...SAN DIEGO, Feb. 17, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...What happened. Investors didn't exactly launch a raid on Viking Therapeutics (NASDAQ: VKTX) stock during Monday's trading session. The shares tumbled by nearly 7% on the back of discouraging news ...Indeed, Viking Therapeutics (NASDAQ:VKTX) stock is up 246% in the last year, providing strong gains for shareholders. Nonetheless, only a fool would ignore the risk that a loss making company ...Discover historical prices for VKTX stock on Yahoo Finance. View daily, weekly or monthly format back to when Viking Therapeutics, Inc. stock was issued. VKTX Related ETFs ; VTI, 0%, +3.43% ; Total Stock Market ETF Vanguard ; DWAS, 0.82%, -2.47% ; DWA Smallcap Momentum Invesco ETF ...Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.

At September 30, 2021, Viking held cash, cash equivalents and short-term investments totaling $216.1 million, compared to $248.4 million as of December 31, 2020. This concludes my financial review ...Mar 30, 2023 · Shares of Viking Therapeutics ( VKTX 6.23%) were up 89.7% for the week as of Thursday afternoon, after being up as much as 95.5% for the week, according to data provided by S&P Global Market ... Viking Therapeutics, Inc. (NASDAQ:VKTX) insiders who bought shares over the past year were rewarded handsomely last week.The stock rose 8.7%, resulting in a US$167m rise in the company's market ...VKTX Stock 12 Months Forecast. $34.00. (187.40% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $34.00 with a high forecast of $40.00 and a low forecast of $28.00. The average price target represents a 187.40% change from the last price of $11.83. Instagram:https://instagram. stock insiders buyinglyft tockai job no tech backgroundalt coins exchange Feb 9, 2023 · Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2022 Results Conference Call February 8, 2023 4:30 AM ETCompany Participants. Stephanie Diaz - Investor Relations. Brian Lian - President and Chief ... 06 Jan, 2021, 16:05 ET. SAN DIEGO, Jan. 6, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the development of novel ... aptv10 dollar gold coin value Viking Therapeutics, Inc. Common Stock (VKTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb … stocks 52 week low Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP agonist compound VK2735 for the ...That's the story for Viking Therapeutics ' ( VKTX 6.46%) share price so far this year. The stock jumped nearly 26% year to date by early March. It subsequently gave up all of those gains and then ...